Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Abstract
Immunotherapy treatments harnessing the patient's immune system herald a new era of personalized medicine, offering hope for curative responses in patients with serious illnesses. Cell-mediated immunity can eliminate cancer cells and provide durable remissions. This often relies on repurposing cytotoxic T cell activity through modified T cell receptors or chimeric antigen receptors. Furthermore, synthetic biology has expanded the cell engineering toolkit to provide immune cells with more functionality, including disease targeting, potency, and safety. We focus on T cell-based immunotherapy, highlighting discoveries of genetic engineering and therapeutic use. We also examine emerging paths that could be undertaken to improve this novel class of drugs, and discuss the challenges of toxicities as well as other limitations of cellular immunotherapy.
Additional Information
© 2019 Elsevier. Available online 11 March 2019. We thank colleagues who commented on various sections of this article. Editorial assistance from C. Sacristán is much appreciated. Limitations on the number of references precluded us from citing many important contributions, and we appreciate the understanding of colleagues whose work could not be cited. The preparation of this review was supported by the University of California Los Angeles/California Institute of Technology Medical Scientist Training Program (R.D.P.), and the Parker Institute for Cancer Immunotherapy (G.L.).Additional details
- Eprint ID
- 93704
- Resolver ID
- CaltechAUTHORS:20190311-152538910
- UCLA/Caltech Medical Scientist Training Program
- Parker Institute for Cancer Immunotherapy
- Created
-
2019-03-11Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field